Find Chronic Idiopathic Constipation (CIC) Clinical Trials Near You
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy and Safety of Plecanatide in Children and Adolescents Age 6 to <18 Years of Age With Functional Constipation (FC)
Status: Recruiting
Location: See all (29) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The goal of this clinical trial is to learn if plecanatide can treat functional constipation in children and adolescents aged 6 to less than 18 years. It will also learn about the safety and pharmacokinetics of plecanatide in this population. The main questions it aims to answer are: * Does plecanatide increase the number of spontaneous bowel movements compared to placebo after 8 weeks of treatment? * What medical problems do participants experience when taking plecanatide? Researchers will compare low-dose plecanatide and high-dose plecanatide to placebo to see if plecanatide improves bowel movement frequency, stool consistency, and constipation-related symptoms. Participants will: * Complete a screening period with daily electronic diary entries to record bowel movements, symptoms, and rescue medication use * Take plecanatide or placebo by mouth once daily for 8 weeks * Continue daily electronic diary entries throughout the study * Attend clinic visits for physical exams, laboratory tests, and assessments of symptoms and safety * Provide blood samples for pharmacokinetic and safety evaluations * Complete questionnaires about constipation symptoms and quality of life
Eligibility
Participation Requirements
Sex: All
Minimum Age: 6
Maximum Age: 17
Healthy Volunteers: f
View:
• Diagnosis of functional constipation (FC) based on Rome IV criteria for children/adolescents.
• Participant and/or legally authorized representative able to provide informed consent/assent.
• Participant/caregiver willing and able to comply with study procedures, including electronic diary (eDiary).
• Completion of ≥5 out of 7 daily diary entries during each of the 2 baseline weeks.
• Stable diet for at least 14 days prior to screening.
• Females of childbearing potential must use highly effective contraception and have negative pregnancy tests.
Locations
United States
Alabama
University of Alabama at Birmingham/Children's of Alabama
NOT_YET_RECRUITING
Birmingham
The Center for Clinical Trials, Inc.
RECRUITING
Mobile
The Center for Clinical Trials, Inc.
RECRUITING
Saraland
Arkansas
HealthStar Research, LLC
RECRUITING
Hot Springs
Applied Research Center of Arkansas
RECRUITING
Little Rock
California
Advanced Research Center, Inc.
RECRUITING
Anaheim
Sun Valley Research Center
NOT_YET_RECRUITING
Imperial
Center for Clinical Trials, LLC
RECRUITING
Paramount
Loma Linda University
NOT_YET_RECRUITING
San Bernardino
Florida
Direct Helpers Research Center
RECRUITING
Hialeah
AppleMedical Research Group, Inc
RECRUITING
Miami
SouthCoast Research Center, Inc.
RECRUITING
Miami
Georgia
Rophe Adult and Pediatric Medicine/SKYCRNG
RECRUITING
Union City
Kansas
AMR Clinical
RECRUITING
El Dorado
AMR Clinical
RECRUITING
Wichita
Louisiana
Willis Knighton Clinical Research
RECRUITING
Shreveport
Maryland
University of Maryland Baltimore
NOT_YET_RECRUITING
Baltimore
Nebraska
Boys Town National Research Hospital
NOT_YET_RECRUITING
Boys Town
Ohio
University Hospitals Cleveland Medical Center
NOT_YET_RECRUITING
Cleveland
PriMED Clinical Research
RECRUITING
Dayton
Oregon
Cyn3rgy Research
RECRUITING
Gresham
Pennsylvania
Frontier Clinical Research, LLC
RECRUITING
Scottdale
Frontier Clinical Research, LLC
RECRUITING
Smithfield
South Carolina
Carolina Family Care
RECRUITING
Charleston
Texas
Austin Regional Clinic
RECRUITING
Austin
Sun Research Institute
RECRUITING
San Antonio
ClinPoint Trials, LLC
RECRUITING
Waxahachie
Virginia
Pediatric Research of Charlottesville, LLC
RECRUITING
Charlottesville
West Virginia
Frontier Clinical Research, LLC
RECRUITING
Kingwood
Contact Information
Primary
Angela Moore, Director
angela.moore@bauschhealth.com
843-877-2756
Backup
Wendy Walton, BSN
wendy.walton@bauschhealth.com
505-917-8552
Time Frame
Start Date:2026-08-18
Estimated Completion Date:2027-10-18
Participants
Target number of participants:180
Treatments
Experimental: Low Dose Plecanatide
Participants will receive weight-based low-dose plecanatide administered orally once daily for 8 weeks.
Experimental: High Dose Plecanatide
Participants will receive weight-based high-dose plecanatide orally once daily for 8 weeks.
Placebo_comparator: Placebo
Participants will receive matching placebo orally once daily for 8 weeks.